FASN and neoplasm: In this respect, the first human study of FASN inhibitor (TVB-2640) monotherapy in advanced tumours showed a disease control rate of 42% (29/69) compared to 70% (37/53) in combination with paclitaxel and exhibited an 11.8% partial response rate in the OC group.